Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AU565 | HER2amp | Luminal | Trametinib | MEK | MAPK | 0.00533 | uM | 7793.036 | 1.0994 | 1.1845 | 1.0741 | |
| BT-474 | HER2amp | Luminal | Geldanamycin | HSP90 | HSP90 | 0.8 | uM | 9157.012 | 0.3610 | -0.3850 | 0.8641 | |
| MDA-MB-361 | HER2amp | Luminal | Mebendazole | 66.7 | uM | 13558.174 | 0.4408 | -0.5250 | 0.5699 | |||
| MDA-MB-361 | HER2amp | Luminal | GSK461364 | PLK1 | PLK | 0.0107 | uM | 9648.001 | 0.9697 | 0.9044 | 0.6289 | |
| SUM44PE | HER2amp | Luminal | Trametinib | MEK | MAPK | 0.133 | uM | 7538.05 | 0.8140 | 0.3837 | 0.5587 | |
| UACC-893 | HER2amp | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 9045.016 | 0.4430 | -0.1885 | 0.9026 | |
| MDA-MB-361 | HER2amp | Luminal | Mebendazole | 0.000853 | uM | 13558.174 | 0.9476 | 0.8197 | 0.5699 | |||
| MDA-MB-361 | HER2amp | Luminal | GSK461364 | PLK1 | PLK | 0.0000853 | uM | 10095.001 | 0.9651 | 0.9230 | 0.9049 | |
| SUM44PE | HER2amp | Luminal | Trametinib | MEK | MAPK | 3.33 | uM | 7538.05 | 0.7144 | 0.0955 | 0.5587 | |
| AU565 | HER2amp | Luminal | Gemcitabine | DNA replication | DNA replication | 28.9 | uM | 7793.011 | 0.1287 | -0.6660 | 1.1456 | |
| HCC1419 | HER2amp | Luminal | L-779450 | BRAF | MAPK | 0.0107 | uM | 12001.166 | 0.8833 | 0.6002 | 0.5565 | |
| MDA-MB-361 | HER2amp | Luminal | GSK461364 | PLK1 | PLK | 1.33 | uM | 9648.001 | 0.5213 | -0.2902 | 0.6289 | |
| SK-BR-3 | HER2amp | Luminal | TPCA-1 | IKK | NFKB | 2.67 | uM | 7527.093 | 0.8258 | 0.7990 | 1.8070 | |
| AU565 | HER2amp | Luminal | Gemcitabine | DNA replication | DNA replication | 0.0462 | uM | 7793.011 | 0.2085 | -0.4910 | 1.1456 | |
| MDA-MB-361 | HER2amp | Luminal | JNK-IN-5A | JNK | JNK | 0.32 | uM | 12379.168 | 1.0507 | 1.2234 | 0.4672 | |
| MDA-MB-361 | HER2amp | Luminal | GSK461364 | PLK1 | PLK | 6.67 | uM | 9648.001 | 0.5617 | -0.2006 | 0.6289 | |
| SK-BR-3 | HER2amp | Luminal | TPCA-1 | IKK | NFKB | 13.3 | uM | 7527.093 | 0.7846 | 0.7487 | 1.8070 | |
| AU565 | HER2amp | Luminal | Gemcitabine | DNA replication | DNA replication | 0.00185 | uM | 7793.011 | 0.9393 | 0.8936 | 1.1456 | |
| MDA-MB-361 | HER2amp | Luminal | Mebendazole | 2.67 | uM | 13558.174 | 0.6073 | -0.1664 | 0.5699 | |||
| HCC1419 | HER2amp | Luminal | GSK461364 | PLK1 | PLK | 6.67 | uM | 9278.001 | 0.9943 | 0.9745 | 0.4429 | |
| SUM44PE | HER2amp | Luminal | Trametinib | MEK | MAPK | 0.667 | uM | 7538.05 | 0.7497 | 0.1943 | 0.5587 | |
| AU565 | HER2amp | Luminal | Gemcitabine | DNA replication | DNA replication | 0.00925 | uM | 7793.011 | 0.8597 | 0.7528 | 1.1456 | |
| MDA-MB-361 | HER2amp | Luminal | Mebendazole | 0.00427 | uM | 13558.174 | 0.9561 | 0.8485 | 0.5699 | |||
| MDA-MB-361 | HER2amp | Luminal | GSK461364 | PLK1 | PLK | 33.3 | uM | 9648.001 | 0.4554 | -0.4274 | 0.6289 | |
| AU565 | HER2amp | Luminal | Trametinib | MEK | MAPK | 16.7 | uM | 7793.012 | 1.0043 | 1.0078 | 1.1030 |